Effect of Venous Thrombotic Events on Overall Survival in Multiple Myeloma: Analysis of Thrombotic Events Occurring in E4A03A Randomized Trial of Lenalidomide Plus High-Dose Dexamethasone (RD) Versus Lenalidomide Plus Low-Dose Dexamethasone (Rd) in Newly Diagnosed Multiple Myeloma, a Trial Coordinated by the Eastern Cooperative Oncology Group (ECOG).

被引：0
|
作者：
Jacobus, Susanna [1 ]
Kumar, Shaji [2 ]
Callander, Natalie Scott [3 ]
Abonour, Rafat [4 ]
Fonseca, Rafael [5 ]
Siegel, David [6 ]
Greipp, Philip [2 ]
Rajkumar, S. Vincent [2 ]
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Mayo Clin, Rochester, MN USA
[3] Univ Wisconsin, Madison, WI USA
[4] Indiana Univ Canc, Indianapolis, IN USA
[5] Mayo Clin, Scottsdale, AZ USA
[6] Hackensack Univ, Med Ctr, Hackensack, NJ USA
来源：
BLOOD | 2008年 / 112卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：613 / 614
页数：2
相关论文
共 50 条
  • [31] Overall Survival (OS) of Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Versus Lenalidomide and Dexamethasone (Rd): Final Analysis from the Randomized Phase 3 Aspire Trial
    Stewart, A. Keith
    Siegel, David
    Ludwig, Heinz
    Facon, Thierry
    Goldschmidt, Hartmut
    Jakubowiak, Andrzej J.
    Miguel, Jesus F. San
    Obreja, Mihaela
    Blaedel, Julie
    Dimopoulos, Meletios A.
    BLOOD, 2017, 130
  • [32] Pomalidomide plus Bortezomib plus Low-Dose Dexamethasone Vs Bortezomib plus Low-Dose Dexamethasone As Second-Line Treatment in Patients with Lenalidomide-Pretreated Multiple Myeloma: A Subgroup Analysis of the Phase 3 Optimismm Trial
    Dimopoulos, Meletios A.
    Weisel, Katja
    Moreau, Philippe
    Anderson, Larry
    White, Darrell J.
    San-Miguel, Jesus F.
    Sonneveld, Pieter
    Engelhardt, Monika
    Jenner, Matthew W.
    Corso, Alessandro
    Duerig, Jan
    Pavic, Michel
    Salomo, Morten
    Yu, Xin
    Tuong Vi Nguyen
    Bensmaine, Amine
    Peluso, Teresa
    Zaki, Mohamed
    Richardson, Paul
    BLOOD, 2018, 132
  • [33] THE FIRST TRIAL: ANALYSIS OF THE ASIAN SUBGROUP OF TRANSPLANT-INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED WITH CONTINUOUS LENALIDOMIDE AND LOW-DOSE DEXAMETHASONE
    Lu, J.
    Lee, J. H.
    Huang, S. Y.
    Qiu, L.
    Lee, J. J.
    Liu, T.
    Yoon, S. S.
    Kim, K.
    Shen, Z. X.
    Eom, H. S.
    Chen, W. M.
    Min, C. K.
    Kim, H. J.
    Lee, J. O.
    Kwak, J. Y.
    Yiu, W.
    Chen, G.
    Ervin-Haynes, A.
    Hulin, C.
    Facon, T.
    HAEMATOLOGICA, 2016, 101 : 548 - 549
  • [34] Impact of Renal Impairment (RI) on Outcomes after Treatment (Tx) with Lenalidomide and Low-Dose Dexamethasone (Rd) in Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): First Trial Results
    Dimopoulos, Meletios A.
    Cheung, Matthew C.
    Roussel, Murielle
    Liu, Ting
    Gamberi, Barbara
    Kolb, Brigitte
    Derigs, H. Guenter
    Eom, Hyeon Seok
    Belhadj, Karim
    Lenain, Pascal
    van der Jagt, Richard H.
    Rigaudeau, Sophie
    Dib, Mamoun
    Hall, Rachel
    Jaccard, Arnaud
    Tosikyan, Axel
    Karlin, Lionel
    Bensinger, William
    Schots, Rik
    Chen, Guang
    Marek, Jennifer
    Ervin-Haynes, Annette
    Facon, Thierry
    BLOOD, 2014, 124 (21)
  • [35] IMPACT OF RENAL IMPAIRMENT ON THE EFFICACY AND SAFETY OF LENALIDOMIDE PLUS LOW-DOSE DEXAMETHASONE (RD) IN CHINESE PATIENTS (PTS) WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM): MM-021 TRIAL
    Zhou, D. B.
    Yu, L.
    Du, X.
    Jin, J.
    Cai, Z.
    Chen, F.
    Li, X.
    Wu, D.
    Meng, F.
    Ai, H.
    Zhang, J.
    Wortman-Vayn, H.
    Mei, J.
    Wang, J.
    Hou, J.
    HAEMATOLOGICA, 2014, 99 : 371 - 371
  • [36] Final Survival Analysis From the FIRST Trial: Lenalidomide Plus Low-Dose Dexamethasone Until Progression (Rd Cont) v Melphalan, Prednisone and Thalidomide (MPT), and Rd for 18 Cycles (Rd18) for Transplant-Ineligible (TNE) Patients (Pts) With Newly Diagnosed Multiple Myeloma
    Facon, Thierry
    Dimopoulos, Meletios Athanasios
    Dispenzieri, Angela
    Catalano, John
    Belch, Andrew R.
    Cavo, Michele
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (01): : E63 - E64
  • [37] Impact of Cytogenetics on Outcomes of Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Continuous Lenalidomide Plus Low-Dose Dexamethasone in the First (MM-020) Trial
    Avet-Loiseau, Herve
    Hulin, Cyrille
    Benboubker, Lofti
    Dimopoulos, Meletios A.
    Belch, Andrew
    Reece, Donna
    Catalano, John
    Pinto, Antonio
    Ludwig, Heinz
    Bahlis, Nizar J.
    Cavo, Michele
    Attal, Michel
    Moreau, Philippe
    Qiu, Lugui
    LeBlanc, Richard
    Schots, Rik
    Rajkumar, S. Vincent
    Marek, Jennifer
    Chen, Guang
    Yiu, Wai
    Ervin-Haynes, Annette
    Facon, Thierry
    BLOOD, 2015, 126 (23)
  • [38] Lenalidomide with Low-Dose Dexamethasone (Rd) Continuously Versus Rd Induction, Tandem MEL140 with Autologous Transplantation and Lenalidomide Maintenance: Planned Interim Analysis of a Prospective Randomized Trial in Patients 60-75 Years of Age with Multiple Myeloma
    Straka, Christian
    Schaefer-Eckart, Kerstin
    Bassermann, Florian
    Timon, Hansen
    Hertenstein, Bernd
    Langer, Christian
    Salwender, Hans
    Knop, Stefan
    Engelhardt, Monika
    Kropff, Martin
    Roesler, Wolf
    Decker, Thomas
    Hebart, Holger
    Frickhofen, Norbert
    Reichle, Albrecht
    Gerecke, Christian
    Metzner, Bernd
    Heidemann, Else
    Brummendorf, Tim H.
    Ababei, Juliane
    Jung, Wolfram E.
    Gramatzki, Martin
    Hentrich, Marcus
    Bojko, Peter
    von Metzler, Ivana
    Kaufmann, Martin
    Naumann, Ralph
    Kubin, Thomas
    Schmidt, Burkhard
    Walther, Jochem
    Dechow, Tobias
    Wandt, Hannes
    Schnabel, Brigitte
    Hinke, Axel
    Einsele, Hermann
    BLOOD, 2014, 124 (21)
  • [39] IMPACT OF PRIOR THERAPY (TX) ON THE EFFICACY AND SAFETY OF LENALIDOMIDE PLUS LOW-DOSE DEXAMETHASONE (RD) IN CHINESE PATIENTS (PTS) WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM): MM-021 TRIAL
    Jin, J.
    Du, X.
    Cai, Z.
    Chen, F.
    Zhou, D. B.
    Yu, L.
    Li, X.
    Wu, D.
    Meng, F.
    Ai, H.
    Wang, J.
    Zhang, J.
    Wortman-Vayn, H.
    Mei, J.
    Hou, J.
    HAEMATOLOGICA, 2014, 99 : 375 - 375
  • [40] A FRAILTY SCALE PREDICTS OUTCOMES IN TRANSPLANT-INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED WITH CONTINUOUS LENALIDOMIDE PLUS LOW-DOSE DEXAMETHASONE IN THE FIRST (MM-020) TRIAL
    Facon, T.
    Hulin, C.
    Dimopoulos, M. A.
    Belch, A.
    Meuleman, N.
    Mohty, M.
    Chen, W. M.
    Kim, K.
    Zamagni, E.
    Rodriguez-Otero, P.
    Renwick, W.
    Rose, C.
    Tempescul, A.
    Boyle, E.
    Palumbo, A.
    Guo, S.
    Monzini, M. S.
    Sturniolo, M.
    Ervin-Haynes, A.
    Fermand, J. P.
    HAEMATOLOGICA, 2016, 101 : 258 - 259
12345